Journal Image
Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)
ISSN (Print): 1871-529X
ISSN (Online): 2212-4063
Epub Abstract Ahead of Print
DOI: 10.2174/1871529X14666140401114301      Price:  $95

Statins for Early Stage Chronic Kidney Disease: an Overview of Reviews

Author(s): TF Galvao, ME AAraujo, AP Penha and MT Silva
Page 1
Objective: To assess the efficacy of statin therapy on early stage chronic kidney diseasethrough an overview of systematic reviews. Methods: We searched for systematic reviews of randomized clinical trials (RCT) on MEDLINE, Embase, Cochrane Library, CRD, and Scopus.Independent reviewers selected the studies and extracted the relevant data. We critically appraised the included systematic reviews with the AMSTAR tool and presented the available data in the studies. Results: From 731 retrieved records, we includedthree systematic reviews. Statins reduced the risk of mortality for all causes and for cardiovascular causes in patients with early stage chronic kidney disease as compared to the control(high-quality evidence).Statins also reduced the incidence of any myocardial infarction, non-fatal myocardial infarction, and stroke (moderate- to high-quality evidence). No differenceswere observed between statins and control upon the incidence of end-stage renal disease or on the outcomesassessed in patients with coronary artery disease and diabetes. Conclusion: Statins reduce the incidence of death and other relevant outcomes in patients with early stage chronic kidney disease and shouldbe considered for such individualswhoalso present hyperlipidemia
Getulio Vargas University Hospital, Federal University of Amazonas, Manaus, AM, Brazil